Lexaria Bioscience (LEXX) Registration filing summary

Company overview and business model

• Focuses on enhancing bioavailability of fat-soluble molecules and APIs using patented DehydraTECH technology for pharmaceuticals, nutraceuticals, and consumer products.

• DehydraTECH enables improved delivery and effectiveness of active ingredients, supporting lower dosing and healthier ingestion methods.

• Technology applicable to a wide range of molecules, including vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, nicotine, cannabinoids, and GLP-1 drugs.

• Business model includes licensing DehydraTECH to third parties and supporting integration into their products.

• Holds patents in the US, Canada, Australia, Europe, India, Mexico, and Japan, with ongoing global patent applications.

Financial performance and metrics

• As of May 31, 2024, 14,323,173 shares of common stock were outstanding.

• The company received approximately $4.7 million in gross proceeds from the exercise of prior warrants.

• Will receive up to $13,855,902 upon full cash exercise of the new warrant.

Use of proceeds and capital allocation

• Proceeds from warrant exercises, if any, will be used for general working capital purposes.